These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

684 related items for PubMed ID: 19249179

  • 1. Multicenter evaluation of the in vitro activity of dalbavancin tested against staphylococci and streptococci in 5 European countries: results from the DECIDE Surveillance Program (2007).
    Biedenbach DJ, Jones RN.
    Diagn Microbiol Infect Dis; 2009 Jun; 64(2):177-84. PubMed ID: 19249179
    [Abstract] [Full Text] [Related]

  • 2. Activity of dalbavancin tested against Staphylococcus spp. and beta-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United States.
    Biedenbach DJ, Ross JE, Fritsche TR, Sader HS, Jones RN.
    J Clin Microbiol; 2007 Mar; 45(3):998-1004. PubMed ID: 17215346
    [Abstract] [Full Text] [Related]

  • 3. Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens.
    Streit JM, Sader HS, Fritsche TR, Jones RN.
    Diagn Microbiol Infect Dis; 2005 Dec; 53(4):307-10. PubMed ID: 15922534
    [Abstract] [Full Text] [Related]

  • 4. Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States Surveillance Program (2004).
    Jones RN, Stilwell MG, Sader HS, Fritsche TR, Goldstein BP.
    Diagn Microbiol Infect Dis; 2006 Feb; 54(2):149-53. PubMed ID: 16426793
    [Abstract] [Full Text] [Related]

  • 5. In vitro activity of dalbavancin and telavancin against staphylococci and streptococci isolated from patients in Canadian hospitals: results of the CANWARD 2007-2009 study.
    Karlowsky JA, Adam HJ, Poutanen SM, Hoban DJ, Zhanel GG, Canadian Antimicrobial Resistance Alliance (CARA).
    Diagn Microbiol Infect Dis; 2011 Mar; 69(3):342-7. PubMed ID: 21353963
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Activity of dalbavancin against staphylococci and streptococci, assessed by BSAC and NCCLS agar dilution methods.
    Mushtaq S, Warner M, Johnson AP, Livermore DM.
    J Antimicrob Chemother; 2004 Sep; 54(3):617-20. PubMed ID: 15321983
    [Abstract] [Full Text] [Related]

  • 9. Update of dalbavancin spectrum and potency in the USA: report from the SENTRY Antimicrobial Surveillance Program (2011).
    Jones RN, Sader HS, Flamm RK.
    Diagn Microbiol Infect Dis; 2013 Mar; 75(3):304-7. PubMed ID: 23357293
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005).
    Sader HS, Watters AA, Fritsche TR, Jones RN.
    BMC Infect Dis; 2007 Apr 18; 7():29. PubMed ID: 17442104
    [Abstract] [Full Text] [Related]

  • 12. Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates.
    Streit JM, Fritsche TR, Sader HS, Jones RN.
    Diagn Microbiol Infect Dis; 2004 Feb 18; 48(2):137-43. PubMed ID: 14972384
    [Abstract] [Full Text] [Related]

  • 13. Bactericidal activity and resistance development profiling of dalbavancin.
    Goldstein BP, Draghi DC, Sheehan DJ, Hogan P, Sahm DF.
    Antimicrob Agents Chemother; 2007 Apr 18; 51(4):1150-4. PubMed ID: 17220411
    [Abstract] [Full Text] [Related]

  • 14. Activity of dalbavancin tested against Gram-positive clinical isolates causing skin and skin-structure infections in paediatric patients from US hospitals (2014-2015).
    Pfaller MA, Mendes RE, Sader HS, Castanheira M, Flamm RK.
    J Glob Antimicrob Resist; 2017 Dec 18; 11():4-7. PubMed ID: 28735053
    [Abstract] [Full Text] [Related]

  • 15. Selection of a surrogate agent (vancomycin or teicoplanin) for initial susceptibility testing of dalbavancin: results from an international antimicrobial surveillance program.
    Jones RN, Sader HS, Fritsche TR, Hogan PA, Sheehan DJ.
    J Clin Microbiol; 2006 Jul 18; 44(7):2622-5. PubMed ID: 16825398
    [Abstract] [Full Text] [Related]

  • 16. Microbiologic characterization of isolates from a dalbavancin clinical trial for catheter-related bloodstream infections.
    Goldstein BP, Jones RN, Fritsche TR, Biedenbach DJ.
    Diagn Microbiol Infect Dis; 2006 Feb 18; 54(2):83-7. PubMed ID: 16458124
    [Abstract] [Full Text] [Related]

  • 17. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
    Jones RN, Sader HS, Fritsche TR, Pottumarthy S.
    Diagn Microbiol Infect Dis; 2007 Jan 18; 57(1):109-16. PubMed ID: 16930923
    [Abstract] [Full Text] [Related]

  • 18. Dalbavancin in-vitro activity obtained against Gram-positive clinical isolates causing bone and joint infections in US and European hospitals (2011-2016).
    Pfaller MA, Flamm RK, Castanheira M, Sader HS, Mendes RE.
    Int J Antimicrob Agents; 2018 Apr 18; 51(4):608-611. PubMed ID: 29277526
    [Abstract] [Full Text] [Related]

  • 19. [Activity of vancomycin, teicoplanin and linezolid in methicillin resistant coagulase-negative Staphylococci isolates from paediatric blood cultures].
    Fajardo Olivares M, Hidalgo Orozco R, Rodríguez Garrido S, Gaona Álvarez C, Sánchez Silos RM, Hernández Rastrollo R, Martínez Tallo E, Cordero Carrasco JL.
    Rev Esp Quimioter; 2012 Mar 18; 25(1):25-30. PubMed ID: 22488538
    [Abstract] [Full Text] [Related]

  • 20. Antimicrobial activity of doripenem tested against prevalent Gram-positive pathogens: results from a global surveillance study (2003-2007).
    Fritsche TR, Sader HS, Stillwell MG, Jones RN.
    Diagn Microbiol Infect Dis; 2009 Apr 18; 63(4):440-6. PubMed ID: 19302928
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.